Last updated: February 24, 2026
What is NDC 00904-7502?
NDC 00904-7502 refers to Blenrep (belantamab mafodotin-blmf), a monoclonal antibody-drug conjugate approved by the FDA in August 2020. It treats relapsed/refractory multiple myeloma in adult patients who have received at least four prior therapies.
Market Size and Trends
Primary Indication: Multiple Myeloma
- Global multiple myeloma market size was valued at approximately $19 billion in 2022.
- The U.S. accounts for roughly 40% of that market, estimated at $7.6 billion.
- Incidence in the U.S.: 34,000 new cases annually[1].
Key Competitors
- Kyprolis (carfilzomib): $2.3 billion globally (2022).
- Darzalex (daratumumab): $7.4 billion globally (2022).
- Empliciti (elotuzumab): $200 million globally (2022).
- Ide-cel (idecabtagene vicleucel): emerging CAR-T therapy.
Market Dynamics
- Increasing prevalence driven by aging populations and improved diagnostics.
- Shift toward immunotherapies and targeted agents.
- Growing innovation: antibody-drug conjugates, CAR-T, bispecific antibodies.
Uptake Factors
- Efficacy demonstrated in multiple trials; overall response rate (ORR) around 30–60%, depending on line of therapy[2].
- FDA approval for heavily pre-treated patients positions it mainly for relapsed/refractory cases.
- Adoption influenced by administration route, side-effect profile, and reimbursement policies.
Price History and Projections
Current Pricing
- List Price (per dose): approximately $16,000.
- Average annual treatment cost: ranges from $170,000 to $200,000, considering recommended dosing schedules and outpatient administration.
Reimbursement Landscape
- Reimbursement rates differ by payer and patient support programs.
- Commercial payers tend to negotiate discounts; Medicaid and Medicare set reimbursement based on prevalent standards.
Market Penetration and Growth Projections
| Year |
Projected Sales (USD billion) |
Growth Rate |
Notes |
| 2022 |
0.15 |
N/A |
Launch phase, limited adoption |
| 2023 |
0.3 |
100% |
Increased acceptance, expanded indications |
| 2024 |
0.5 |
66% |
Broader uptake, competition emerging |
| 2025 |
0.9 |
80% |
Integration into treatment protocols |
- The compound annual growth rate (CAGR) is estimated at approximately 63% through 2025.
Influencing Factors
- Clinical trial outcomes favoring label extensions.
- Competitive pressures from pipeline drugs.
- Regulatory considerations for expanded indications.
Strategic Market Considerations
- Pricing strategies should align with value-based assessments.
- Diversification through international markets remains critical.
- Patient support and access programs influence market penetration.
Regulatory and Reimbursement Outlook
- Pending label expansions could further increase revenue (e.g., earlier lines of therapy).
- Reimbursement pressures may drive discounts, affecting net price.
- New entrants, including CAR-T therapies and bispecifics, could impact growth.
Risks and Opportunities
Risks
- Manufacturing complexity of antibody-drug conjugates.
- Competition from emerging therapies.
- Potential safety concerns leading to label restrictions.
Opportunities
- Expanding into earlier treatment lines.
- Developing combination regimens.
- International launches and partnerships.
Key Takeaways
- NDC 00904-7502 (Blenrep) has a niche market mainly in relapsed/refractory multiple myeloma.
- Current annual sales approximate $150–200 million, with growth driven by increased indication use and market acceptance.
- Price projections suggest rapid growth through 2025, with a CAGR near 63%.
- Market expansion depends on clinical success, regulatory approvals, and competitive dynamics.
FAQs
1. What factors influence the price of Blenrep?
Pricing is impacted by manufacturing costs, clinical efficacy, competition, payer negotiations, and value-based assessments.
2. How does Blenrep compare against competing therapies?
Blenrep offers targeted therapy for heavily pre-treated patients. Response rates vary but are favorable for its category; competition includes CAR-T and bispecific antibodies.
3. What are potential barriers to market growth?
Safety profile concerns, high treatment costs, manufacturing complexity, and emerging therapies could limit expansion.
4. Are there upcoming regulatory decisions that could impact pricing?
Yes, potential label extensions or approvals for earlier lines of treatment could increase sales and influence pricing strategies.
5. How might international markets affect sales?
Global approvals and access programs can significantly expand the market, influencing both revenue and pricing.
References
[1] American Cancer Society. (2022). Cancer Facts & Figures 2022.
[2] Kumar, S. K., Rajkumar, S. V., & Richardson, P. G. (2021). Multiple Myeloma. Hematology/Oncology Clinics of North America, 35(6), 1159–1175.
